Figure 1: Glycan array of Ad37 knob interactions with 260 different glycans. Figure 2: Ad37 binding to the corneal epithelial cell surface depends on fiber knob binding to molecules containing the ...

Vernal keratoconjunctivitis (VKC) is an allergic eye disease that especially affects young boys. The most common symptoms are itching, photophobia, burning, and tearing. The most common signs are ...

DUBLIN--(BUSINESS WIRE)--The "Vernal Keratoconjunctivitis (VKC) Epidemiology Forecast to 2030" report has been added to ResearchAndMarkets.com's offering. This report delivers an in-depth ...

Conjunctivitis and keratoconjunctivitis are two similar eye conditions. They both cause the eyes to become pink or red and may cause itchiness and irritation. Conjunctiva is the name for the ...

Atopic keratoconjunctivitis (AKC) is a rare but serious eye condition. AKC can cause various symptoms, including increased sensitivity to light, itching and burning eyes, and blurred vision.

Keratoconjunctivitis is when you have both keratitis and conjunctivitis at the same time. Keratitis is inflammation of the cornea, the clear dome that covers the iris and the pupil. Conjunctivitis ...

The global vernal keratoconjunctivitis market is poised for significant expansion over the next decade, driven by the increasing prevalence of conjunctivitis cases, particularly in emerging economies.

It occurs almost exclusively in vernal keratoconjunctivitis and atopic keratoconjunctivitis. It is characterized by punctate and then confluent corneal ulceration, plaque formation, increased risk ...

The global Vernal Keratoconjunctivitis Market is expected to garner a market value of US$ 436.9 Million in 2023 and is expected to accumulate a market value of US$ 782.42 Million by registering a CAGR ...

Verkazia is an oil-in-water cationic emulsion that works by inhibiting T-cell activation and reducing the level of immune cells and mediators. Verkazia ® (cyclosporine ophthalmic emulsion) 0.1% ...

Vernal keratoconjunctivitis (VKC) is a chronic, bilateral, allergic condition primarily affecting children and young adults. It is a seasonal allergic inflammatory disease of the eye with episodes ...

Please provide your email address to receive an email when new articles are posted on . The FDA has accepted Santen’s new drug application for cyclosporine topical ophthalmic emulsion 0.1% to ...